TABLE 3.
Graft outcomes at 12 mo
| Desensitization (n = 10) | No induction (n = 48) | HR (95% CI) | P a | |
|---|---|---|---|---|
| Graft failure | 1 (10.0) | 1 (2.1) | 5.1 (0.32-80.97) | 0.25 |
| Rejection | ||||
| Any severity | 2 (20.0) | 23 (47.9) | 0.36 (0.08-1.51) | 0.16 |
| Grade ≥2 rejection | 1 (10.0) | 8 (16.7) | 0.59 (0.07-4.69) | 0.62 |
| Acute cellular rejection | ||||
| Any severity | 1 (10.0) | 17 (35.4) | 0.24 (0.03-1.83) | 0.17 |
| Grade ≥2R | 1 (10.0) | 5 (10.4) | 1.01 (0.12-8.62) | 0.99 |
| Antibody-mediated rejection | ||||
| Any severity | 1 (10.0) | 13 (27.1) | 0.36 (0.05-2.74) | 0.32 |
| Grade ≥2 pAMRb | 0 (0.0) | 3 (6.3) | – | 0.62 |
| ISHLT CAV1 | 2 (20.0) | 12 (25.0) | 0.79 (0.20-3.17) | 0.76 |
| Desensitization (n = 10) | Induction (n = 46) | HR (95% CI) | P | |
| Graft failureb | 1 (10.0) | 0 (0.0) | – | 0.72 |
| Rejection | ||||
| Any severity | 2 (20.0) | 11 (23.9) | 0.93 (0.21-4.18) | 0.92 |
| Grade ≥2 rejection | 1 (10.0) | 1 (2.2) | 5.42 (0.34-86.78) | 0.23 |
| Acute cellular rejection | ||||
| Any severity | 1 (10.0) | 6 (13.0) | 0.81 (0.10-6.70) | 0.84 |
| Grade ≥2Rb | 1 (10.0) | 0 (0.0) | – | 0.75 |
| Antibody-mediated rejection | ||||
| Any severity | 1 (10.0) | 8 (17.4) | 0.63 (0.08-5.03) | 0.66 |
| Grade ≥2 pAMRb | 0 (0.0) | 1 (2.2) | – | 0.78 |
| ISHLT CAV1 | 2 (20.0) | 7 (15.2) | 1.43 (0.25-8.26) | 0.65 |
aCox proportional hazards models were used for the analysis of these time-to-event outcomes.
bHR and 95% CI could not be determined as there were 0 events in at least 1 of the groups.
CAV, cardiac allograft vasculopathy; ISHLT, International Society of Heart and Lung Transplantation; pAMR, pathologic antibody-mediated rejection.